A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: A Kansai Clinical Oncology Group study (KCOG0015 trial)

Gynecologic Oncology

Volumn 120, Issue 2, 2011, Pages 193-197

  Ito, Kimihiko ^a   Tsubamoto, Hiroshi ^b   Itani, Yoshio ^c   Kuroboshi, Haruo ^d   Fujita, Hiroyuki ^e   Nobunaga, Toshikatsu ^f   Coleman, Robert L ^g  

^a KANSAI ROSAI HOSPITAL   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^f Hyogo Prefectural Nishinomiya Hospital   (Japan)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carboplatin; Chemotherapy; Dose dense; Dose intense; Endometrial cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ERYTHROCYTE TRANSFUSION; FEASIBILITY STUDY; FEMALE; HEART ARRHYTHMIA; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; QUALITY OF LIFE; RISK FACTORS;

EID: 79251595226     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.10.025     Document Type: Article

References (26)

1. T. Matsuda, T. Marugame, K. Kamo, K. Katanoda, W. Ajiki Japan Cancer Surveillance Research Group Cancer incidence and incidence rates in Japan in 2003: dased on data from 13 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project Jpn J Clin Oncol 39 2009 850 858
2. H.M. Keys, J.A. Roberts, V.L. Brunetto, R.J. Zaino, N.M. Spirtos, and J.D. Bloss A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 744 751
3. F.V. Price, R.P. Edwards, J.L. Kelley, A.J. Kunschner, and L.A. Hart A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report Semin Oncol 24 5, suppl. 15 1997 S15-78-S15-82
4. P.J. Hoskins, K.D. Swenerton, J.A. Pike, F. Wong, P. Lim, and C. Acquino-Parsons Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study J Clin Oncol 19 20 2001 4048 4053
5. P. Rosenberg, H. Andersson, K. Boman, M. Ridderheim, B. Sorbe, and U. Puistola Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum Acta Oncol 41 5 2002 418 424
6. F.A. Greco, M. Thomas, and J.D. Hainsworth One-hour paclitaxel infusions: review of safety and efficacy Cancer J Sci Am 5 3 1999 179 191
7. A.H. Calvert, D.R. Newell, L.A. Gumbrell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 11 1989 1748 1756
8. R.W. Jelliffe Creatinine clearance: bedside estimate Ann Intern Med 79 4 1973 604 605
9. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 2000 205 216
10. K. Kobayashi, F. Takeda, S. Teramukai, I. Gotoh, H. Sakai, and S. Yoneda A cross-validation of the European Organization for Research and Treatment of Cancer QLQ-C30 (EORTC QLQ-C30) for Japanese with lung cancer Eur J Cancer 34 6 1998 810 815
11. L.R. Duska, R. Berkowitz, U. Matulonis, M. Muto, A. Goodman, and J.F. Mcintyre A pilot traial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer Gynecol Oncol 96 2005 198 203
12. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Ass 1958 457 481
13. A.A. Secord, L.J. Havrilesky, M.E. Carney, J.T. Soper, D.L. Clarke-Pearson, and G.C. Rodriguez Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer Int J Clin Oncol 12 1 2007 31 36
14. T. Tabata, K. Tanida, T. Umekawa, T. Shiozaki, E. Kondo, and K. Nagao Weekly low-dose paclitaxel and carboplatin therapy in gynecological cancer patients with venous thrombosis Anticancer Res 28 6B 2008 3971 3975
15. I. Vandenput, I. Vergote, K. Leunen, P. Berteloot, P. Neven, and F. Amant Leuven dose-dense paclitaxel/carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma Int J Gynecol Cancer 19 6 2009 1147 1151
16. J.T. Thigpen, H.J. Buchsbaum, C. Mangan, and J.A. Blessing Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Cancer Treat Rep 63 1 1979 21 27
17. F. Calero, E. Asins-Codoner, J. Jimeno, E.F. Rodriguez, J. Mendana, and J. Iglesias Epirubicin in advanced endometrial adenocarcinoma: a phase II study of the Grupo Ginecologico Español para el Tratamiento Oncologico (GGETO) Eur J Cancer 27 7 1991 864 866
18. J.T. Thigpen, J.A. Blessing, H. Homesley, W.T. Creasman, and G. Sutton Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study Gynecol Oncol 33 1 1989 68 70
19. J.B. Green III, S. Green, D.S. Alberts, R. O'Toole, E.A. Surwit, and J.W. Noltimier Carboplatin therapy in advanced endometrial cancer Obstet Gynecol 75 4 1990 696 700
20. A. Lissoni, G. Zanetta, G. Losa, A. Gabriele, G. Parma, and C. Mangioni Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer Ann Oncol 7 8 1996 861 863
21. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, and R.A. Burger Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study J Clin Oncol 22 19 2004 3902 3908
22. G.F. Fleming, V.L. Brunetto, D. Cella, K.Y. Look, G.C. Reid, and A.R. Munkarah Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 11 2004 2159 2166
23. T. Hidaka, T. Nakamura, T. Shima, H. Yuki, and S. Saito Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma J Obstet Gynaecol Res 32 3 2006 330 337
24. M.A. Sovak, M.L. Hensley, J. Dupont, N. Ishill, K.M. Alektiar, and N. Abu-Rustum Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study Gynecol Oncol 103 2 2006 451 457
25. N. Katsumata, M. Yasuda, F. Takahashi, S. Isonishi, T. Jobo, and D. Aoki Japanese Gynecologic Oncology Group. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial Lancet 374 9698 2009 1331 1338
26. C. Aghajanian, M.W. Sill, K. Darcy, B. Greer, D.S. McMeekin, and P.G. Rose A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group (GOG) study J Clin Oncol 27 2009 15s (abstr 5531)